Alpha Cognition Management
Management criteria checks 2/4
Alpha Cognition's CEO is Michael McFadden, appointed in Apr 2021, has a tenure of 5.25 years. total yearly compensation is $3.62M, comprised of 17.2% salary and 82.8% bonuses, including company stock and options. directly owns 0.065% of the company’s shares, worth $113.85K. The average tenure of the management team and the board of directors is 4 years and 4.8 years respectively.
Key information
Michael McFadden
Chief executive officer
US$3.6m
Total compensation
| CEO salary percentage | 17.25% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 4yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
ACOG: Phase 4 Tolerability Study Will Drive Future Alzheimer’s Launch Traction
The updated analyst price target for Alpha Cognition shifts from about $20 to roughly $14.67, as analysts factor in revised assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, while still highlighting the market opportunity for Zunveyl in treating mild to moderate Alzheimer's dementia. Analyst Commentary Recent Street research on Alpha Cognition focuses on how Zunveyl, its prodrug of galantamine for mild to moderate Alzheimer’s dementia, might translate into commercial traction and support the revised valuation framework behind the updated price target.
ACOG: Early Dementia Therapy Launch Will Drive Bullish Repricing Potential
Analysts have adjusted their 12 month price target for Alpha Cognition to $12 from $14, citing early commercialization of Zunveyl for mild to moderate Alzheimer's dementia and what they view as a significant market opportunity, with high patient and prescriber willingness to try the therapy. Analyst Commentary Recent research coverage on Alpha Cognition has focused on the early commercialization of Zunveyl and the perceived market opportunity in mild to moderate Alzheimer's dementia.
Long Term Care Adoption And Real World Studies Will Transform This Cognitive Therapy Narrative
Catalysts About Alpha Cognition Alpha Cognition develops and commercializes therapies for cognitive disorders, with a primary focus on Alzheimer’s disease through its oral treatment ZUNVEYL. What are the underlying business or industry changes driving this perspective?Payer Friction And Slow Adoption Will Challenge Alzheimer’s Therapy Before Long Term Potential Emerges
Catalysts About Alpha Cognition Alpha Cognition is a biopharmaceutical company focused on commercializing ZUNVEYL for mild to moderate Alzheimer’s disease and advancing related formulations and indications. What are the underlying business or industry changes driving this perspective?We Think Alpha Cognition (NASDAQ:ACOG) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Interested To See How Alpha Cognition (NASDAQ:ACOG) Uses Its Cash Hoard To Grow
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$25m |
| Dec 31 2025 | US$4m | US$625k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$20m |
| Mar 31 2025 | n/a | n/a | -US$12m |
| Dec 31 2024 | US$944k | US$500k | -US$15m |
| Sep 30 2024 | n/a | n/a | -US$15m |
| Jun 30 2024 | n/a | n/a | -US$16m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$2m | US$500k | -US$14m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$1m | US$500k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$10m |
| Dec 31 2021 | US$430k | US$414k | -US$20m |
Compensation vs Market: Michael's total compensation ($USD3.62M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael McFadden (59 yo)
Mr. Michael E. McFadden, BBA, serves as Chief Executive Officer at Alpha Cognition Inc. since April 12, 2021 and serves as its Director since March 28, 2021. Mr. McFadden served as Chief Commercial Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$3.62m | 0.065% $ 113.8k | |
| Founder | 5.3yrs | US$246.00k | 1% $ 1.8m | |
| VP of Finance & Accounting and Interim CFO | 1.8yrs | US$464.51k | 0% $ 0 | |
| Chief Operating Officer | 2.8yrs | US$2.41m | 0.65% $ 1.1m | |
| Chief Scientific Officer | 5.2yrs | US$180.00k | no data | |
| Head of Compliance | no data | no data | no data | |
| Vice President of Marketing & Commercial Strategy | less than a year | no data | no data |
Experienced Management: ACOG's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$3.62m | 0.065% $ 113.8k | |
| Founder | 5.3yrs | US$246.00k | 1% $ 1.8m | |
| Independent Director | 8.7yrs | US$248.50k | 0.054% $ 95.3k | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Independent Chairman of the Board | 1.3yrs | US$185.00k | 0.069% $ 120.8k | |
| Independent Director | 5.3yrs | US$247.00k | 0.10% $ 180.8k | |
| Independent Director | less than a year | no data | no data | |
| Chair of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data |
Experienced Board: ACOG's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/15 12:20 |
| End of Day Share Price | 2026/07/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Cognition Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Nazibur Rahman | Maxim Group |
| Ryan Deschner | Raymond James & Associates |